SOPHiA GENETICS (SOPH) CEO Jurgi Camblong Sells 31,940 Shares
Jurgi Camblong, CEO of SOPHiA GENETICS, sold shares on June 26, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Jurgi Camblong, Chief Executive Officer at SOPHiA GENETICS SA ($SOPH), sold 31,940 shares on June 26, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $SOPH is down 7.1% after 1 week, down 1.7% after 1 month and up 17.0% to date (from the $5.75 close on Jun 26, 2026).
SOPH
SOPHiA GENETICS SA
Key Points
- Jurgi Camblong, CEO of SOPHiA GENETICS, sold 31,940 shares on June 26, 2026, with no planned transaction.
- Shares of SOPHiA GENETICS traded at $5.75 on NasdaqGS, with a market cap of $482.4 million.
- BTIG reiterated its buy rating with an $8 target, while insiders made notable trades recently.
Get $SOPH trade alerts by text
We text you when insiders, Congress or big funds trade $SOPH. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated SOPHiA GENETICS SA alert may contain errors. Disclosures
Jurgi Camblong, the CEO of SOPHiA GENETICS SA, sold 31,940 shares of the company on June 26, 2026. This transaction was not part of a pre-planned trading arrangement. Shares of SOPHiA GENETICS traded at $5.75 on the NasdaqGS on the same day.
Insider Buying and Selling at SOPHiA GENETICS SA
On June 26, 2026, Jurgi Camblong, CEO of SOPHiA GENETICS, executed several transactions. He sold 31,940 shares without a predetermined plan, in addition to a planned sale of 50,069 shares at an average price of $5.80. Earlier, on June 25, he sold 1,373 shares at $5.7, and other executives like Philippe Menu and Abhimanyu Verma made planned sales as well.
SOPHiA GENETICS SA Stock Down 18.0%
Shares of SOPHiA GENETICS, trading on NasdaqGS under the ticker SOPH, were priced at $5.75 on Tuesday. The company has a market capitalization of approximately $482.4 million. It operates with a negative forward P/E ratio of -10.27, indicating it is not currently profitable. The stock's 52-week range is between $2.81 and $5.94, with a 50-day moving average of $5.07 and a 200-day moving average of $4.72. The company maintains a current ratio of 2.06 and a quick ratio of 1.71, alongside a debt-to-equity ratio of 136.63.
Analysts Set New Price Targets
On June 15, 2026, BTIG reiterated its buy rating on SOPHiA GENETICS with a price target of $8. Guggenheim also maintained a buy rating with a target of $7 earlier in the year. The consensus among analysts is a strong buy, with an average target price of $8 based on three opinions.
About SOPHiA GENETICS
SOPHiA GENETICS SA is a healthcare technology company based in Rolle, Switzerland. It provides a cloud-native software platform called SOPHiA DDM that helps analyze and generate insights from complex medical data. The platform is used by hospitals, laboratories, and biopharmaceutical companies worldwide. Founded in 2011, the company is led by CEO George A. Cardoza and employs around 415 people.
Bottom Line
Insider transactions at SOPHiA GENETICS, including those by CEO Jurgi Camblong, offer a glimpse into the company's internal dynamics. Investors keep an eye on such moves to gauge management's confidence in the business. As a reminder, these trades are based on past filings and may not represent current positions. Analysts continue to show optimism with a strong buy consensus and targets above the current trading price.
Related Filing Alerts
Source: Jurgi Camblong's Form 4 filing on $SOPH (Jun 26, 2026). Find the original filing: SOPH Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts